| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Bis-PEG13-NHS ester targets primary amines on proteins, peptides, and other biomolecules. The NHS ester groups react efficiently with primary amines, such as the ε-amino group of lysine residues or the N-terminal amino group of polypeptides, to form stable amide bonds. The 13-unit PEG chain provides a long, hydrophilic spacer between the two reactive groups, allowing for the crosslinking of proteins with minimal steric hindrance. The PEG spacer also enhances the solubility and reduces the immunogenicity of the crosslinked conjugates.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system. An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
In vitro, Bis-PEG13-NHS ester is used to crosslink proteins and peptides for various applications, including the preparation of protein-protein conjugates, protein-PEG conjugates, and protein-drug conjugates. The compound's long PEG spacer allows for the formation of flexible and soluble crosslinked products. The NHS ester groups react rapidly with amines at physiological pH, enabling efficient crosslinking under mild conditions. The crosslinked products can be analyzed by SDS-PAGE and mass spectrometry. |
| ln Vivo |
In vivo, Bis-PEG13-NHS ester-based crosslinked proteins have the potential to demonstrate improved pharmacokinetic properties due to the PEG spacer. The PEG chain increases the hydrodynamic volume of the protein, reducing renal clearance and prolonging the half-life in circulation. The PEG spacer also minimizes opsonization and recognition by the reticuloendothelial system, reducing immunogenicity. These properties make Bis-PEG13-NHS ester a valuable tool for the development of PEGylated therapeutics.
|
| Enzyme Assay |
In vitro crosslinking assays for Bis-PEG13-NHS ester are performed by incubating the compound with a protein or peptide of interest in a buffer at pH 7-8. The reaction is typically carried out at room temperature for 1-2 hours. The extent of crosslinking is assessed by SDS-PAGE, size-exclusion chromatography, or mass spectrometry. The efficiency of crosslinking can be optimized by varying the molar ratio of the compound to the protein.
|
| Cell Assay |
In vitro cellular experiments for Bis-PEG13-NHS ester-based conjugates are performed to evaluate their biological activity and cytotoxicity. Cells are treated with the crosslinked protein or conjugate, and the effects on cell viability, proliferation, and function are assessed. The cellular uptake of the conjugate can be assessed using fluorescently labeled proteins. These experiments are essential for characterizing the biological properties of the crosslinked products.
|
| Animal Protocol |
In vivo animal studies for Bis-PEG13-NHS ester-based conjugates are conducted using mouse or rat models. The conjugate is administered via intravenous, intraperitoneal, or subcutaneous injection. The pharmacokinetic properties, including half-life and bioavailability, are evaluated from plasma samples. The efficacy of the conjugate is evaluated by measuring the desired therapeutic outcome. The compound's safety and tolerability are also assessed.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Bis-PEG13-NHS ester-based conjugates are improved by the PEG spacer. The hydrophilic PEG chain increases the hydrodynamic volume, reducing renal clearance and prolonging the half-life in circulation. The PEG chain also minimizes opsonization and recognition by the reticuloendothelial system. These properties result in improved systemic exposure and reduced immunogenicity.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Bis-PEG13-NHS ester-based conjugates is generally favorable due to the biocompatibility of PEG. However, high doses of PEGylated compounds can sometimes lead to vacuolation in tissues such as the renal proximal tubules. In preclinical studies, toxicity is assessed by monitoring body weight, clinical signs, and histopathological changes in major organs.
|
| References | |
| Additional Infomation |
Bis-PEG13-NHS ester is a homobifunctional PEG-based crosslinker used for the crosslinking of proteins, peptides, and other amine-containing molecules. Its 13-unit PEG chain provides a long, hydrophilic spacer that enhances the solubility and pharmacokinetic properties of the crosslinked conjugates. The NHS ester groups react efficiently with primary amines, enabling mild and efficient crosslinking. As a research tool, Bis-PEG13-NHS ester is essential for the development of PEGylated proteins, protein-protein conjugates, and other bioconjugates.
|
| Molecular Formula |
C38H64N2O21
|
|---|---|
| Molecular Weight |
884.915574073792
|
| Exact Mass |
884.4
|
| CAS # |
2221949-00-2
|
| Related CAS # |
1008402-79-6;
|
| PubChem CID |
75535126
|
| Appearance |
Colorless to off-white solid-liquid Mixture
|
| LogP |
-3.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
46
|
| Heavy Atom Count |
61
|
| Complexity |
1080
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)N(C1=O)OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)ON2C(=O)CCC2=O
|
| InChi Key |
OVDFFVRBNAHLOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C38H64N2O21/c41-33-1-2-34(42)39(33)60-37(45)5-7-47-9-11-49-13-15-51-17-19-53-21-23-55-25-27-57-29-31-59-32-30-58-28-26-56-24-22-54-20-18-52-16-14-50-12-10-48-8-6-38(46)61-40-35(43)3-4-36(40)44/h1-32H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1300 mL | 5.6502 mL | 11.3005 mL | |
| 5 mM | 0.2260 mL | 1.1300 mL | 2.2601 mL | |
| 10 mM | 0.1130 mL | 0.5650 mL | 1.1300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
